Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in relapsed or refractory multiple myeloma
NL-OMON36750Phase 3Withdrawn
- Sponsor
- Janssen Biologics B.V.
- Start
- Mar 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Sylvant + Velcade + dexamethasone with Placebo + Velcade + dexamethasone (2 arms). Primary endpoint: Progression-free survival. Planned start Mar 2011; status: withdrawn.
02
Drugs
siltuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON36750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36750.